Literature DB >> 28674089

Grounding Cardio-Oncology in Basic and Clinical Science.

Javid Moslehi1, Dulguun Amgalan2, Richard N Kitsis1.   

Abstract

Entities:  

Keywords:  cardio-oncology; cardiomyopathies; drug therapy; personalized medicine

Mesh：

Year:  2017        PMID： 28674089      PMCID： PMC5535811          DOI： 10.1161/CIRCULATIONAHA.117.025393

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  5 in total

1.  Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.

Authors:  Michael S Ewer; Scott M Lippman
Journal:  J Clin Oncol       Date:  2005-05-01       Impact factor: 44.544

Review 2.  Cardiovascular Toxic Effects of Targeted Cancer Therapies.

Authors:  Javid J Moslehi
Journal:  N Engl J Med       Date:  2016-10-13       Impact factor: 91.245

3.  Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.

Authors:  Daniela Cardinale; Alessandro Colombo; Giulia Bacchiani; Ines Tedeschi; Carlo A Meroni; Fabrizio Veglia; Maurizio Civelli; Giuseppina Lamantia; Nicola Colombo; Giuseppe Curigliano; Cesare Fiorentini; Carlo M Cipolla
Journal:  Circulation       Date:  2015-05-06       Impact factor: 29.690

4.  Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation.

Authors:  Yoshihiko Ichikawa; Mohsen Ghanefar; Marina Bayeva; Rongxue Wu; Arineh Khechaduri; Sathyamangla V Naga Prasad; R Kannan Mutharasan; Tejaswitha Jairaj Naik; Hossein Ardehali
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

Review 5.  Emerging paradigms in cardiomyopathies associated with cancer therapies.

Authors:  Bonnie Ky; Pimprapa Vejpongsa; Edward T H Yeh; Thomas Force; Javid J Moslehi
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367
  5 in total
  12 in total

Review 1.  Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease.

Authors:  Dominic P Del Re; Dulguun Amgalan; Andreas Linkermann; Qinghang Liu; Richard N Kitsis
Journal:  Physiol Rev       Date:  2019-10-01       Impact factor: 37.312

Review 2.  Cancer therapy-induced cardiovascular toxicity: old/new problems and old drugs.

Authors:  Andreas M Beyer; Marcelo G Bonini; Javid Moslehi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-06-07       Impact factor: 4.733

3.  p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities.

Authors:  Jie Li; Ping-Yuan Wang; Nathaniel A Long; Jie Zhuang; Danielle A Springer; Jizhong Zou; Yongshun Lin; Christopher K E Bleck; Ji-Hoon Park; Ju-Gyeong Kang; Paul M Hwang
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-05       Impact factor: 11.205

4.  Cardiac fibrosis in oncologic therapies.

Authors:  René R Sevag Packard
Journal:  Curr Opin Physiol       Date:  2022-08-08

5.  Assessment of mitophagy in human iPSC-derived cardiomyocytes.

Authors:  Mingchong Yang; Ji-Dong Fu; Jizhong Zou; Divya Sridharan; Ming-Tao Zhao; Harpreet Singh; Judith Krigman; Mahmood Khan; Gang Xin; Nuo Sun
Journal:  Autophagy       Date:  2022-02-27       Impact factor: 13.391

Review 6.  Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity.

Authors:  Lars Michel; Tienush Rassaf; Matthias Totzeck
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

7.  Left Ventricular Mass Change After Anthracycline Chemotherapy.

Authors:  Jennifer H Jordan; Sharon M Castellino; Giselle C Meléndez; Heidi D Klepin; Leslie R Ellis; Zanetta Lamar; Sujethra Vasu; Dalane W Kitzman; William O Ntim; Peter H Brubaker; Nathaniel Reichek; Ralph B D'Agostino; W Gregory Hundley
Journal:  Circ Heart Fail       Date:  2018-07       Impact factor: 8.790

8.  The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity.

Authors:  Lori Minasian; Eileen Dimond; Myrtle Davis; Bishow Adhikari; Richard Fagerstrom; Carol Fabian; Justin Floyd; Joseph M Unger; Pamela S Douglas; Karen M Mustian; Eric J Chow; Steven Lipshultz; W Gregory Hundley; Saro Armenian; Bonnie Ky
Journal:  JACC CardioOncol       Date:  2019-09-24

9.  A small-molecule allosteric inhibitor of BAX protects against doxorubicin-induced cardiomyopathy.

Authors:  Dulguun Amgalan; Thomas P Garner; Ryan Pekson; Xiaotong F Jia; Mounica Yanamandala; Victor Paulino; Felix G Liang; J Jose Corbalan; Jaehoon Lee; Yun Chen; George S Karagiannis; Luis Rivera Sanchez; Huizhi Liang; Swathi-Rao Narayanagari; Kelly Mitchell; Andrea Lopez; Victoria Margulets; Marco Scarlata; Gaetano Santulli; Aarti Asnani; Randall T Peterson; Rachel B Hazan; John S Condeelis; Maja H Oktay; Ulrich Steidl; Lorrie A Kirshenbaum; Evripidis Gavathiotis; Richard N Kitsis
Journal:  Nat Cancer       Date:  2020-03-02

Review 10.  Shexiang Baoxin Pill, Derived From the Traditional Chinese Medicine, Provides Protective Roles Against Cardiovascular Diseases.

Authors:  Li Lu; Xiaodong Sun; Chen Chen; Yating Qin; Xiaomei Guo
Journal:  Front Pharmacol       Date:  2018-11-14       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.